Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Enfortumab vedotin with pembrolizumab for bladder cancer

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, outlines his research highlights from the 2020 ASCO GU meeting. Dr Sonpavde discusses the combination of enfortumab vedotin and pembrolizumab for metastatic urothelial carcinoma as well as the ATLAS trial (NCT03397394). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.